



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/550,681	09/26/2005	Jerachmiel (Yori) Appelbaum	J0246.70000US00	8344
23628	7590	12/07/2009		
WOLF GREENFIELD & SACKS, P.C. 600 ATLANTIC AVENUE BOSTON, MA 02210-2206			EXAMINER	
			PACKARD, BENJAMIN J	
ART UNIT		PAPER NUMBER		
1612				
MAIL DATE		DELIVERY MODE		
12/07/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/550,681	Applicant(s) APPELBAUM, JERACHMIEL (YORI)
	Examiner Benjamin Packard	Art Unit 1612

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 17 August 2009.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 44-55 is/are pending in the application.
 - 4a) Of the above claim(s) 55 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 44-54 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____
- 5) Notice of Informal Patent Application
- 6) Other: _____

DETAILED ACTION

Applicants' arguments, filed 08/17/09, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

Claim Rejections - 35 USC § 103

Claims 44-54 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Carter et al (Biochemical and Biophysical Research Communications, Vol 297, Iss 4, (2002) 1062-1070) in view of Krajewska et al (Cancer Research 57:8 (1997) 1605-1613).

Applicants assert Carter only teaches TPEN as an experimental tool to reduce the Zn²⁺ levels of the cells and that the combination of the two references would be exceedingly difficult to envision. Further Applicants assert Carter teaches against using TPEN as an agent for treating metastasis where the pro-apoptotic effect would indiscriminately kill both cancer cells and healthy cells. Finally, Applicants assert treating a metastatic tumor by inducing apoptosis is not related to a method of inhibiting the tumor cellular invasion and/or tumor metastasis.

Examiner disagrees. First, while TPEN is used as a tool in Carter, the skilled artisan would recognize that such a tool would be useful also as a therapeutic agent, given TPEN have the ability to produce the desire effect, i.e. reducing the Zn²⁺ levels in the cell line.

Second, just because an agent may indiscriminately kill both cancer cells and healthy cells does not teach away from administration of the active agent. Many anti-cancer agents indiscriminately kill cells, but the focused administration thereof overcomes such a concern.¹

Finally, Examiner disagrees with Applicant's interpretation of the instant method. Specifically, Applicants appear to be arguing the claims are directed at stopping malignant cells which have already progress through metastasis. Examiner notes the claims have no such limitation, but simply require the inhibition of tumor cellular invasion and tumor metastasis. Thus, where a cancer cell line known to progress to metastasis is administered an agent which causes apoptosis, the cancerous cells will be killed off and not enter the "metastasis" phase. Under this reasoning, the treatment of the cell line in fact inhibits tumor cellular invasion in a mammal.

Conclusion

No claims allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the

¹ Walter et al, Neurosurgery: December 1995 - Volume 37 - Issue 6 - p 1129-1145, abstract only,

Art Unit: 1612

shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Benjamin Packard whose telephone number is 571-270-3440. The examiner can normally be reached on M-F 8-5 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Frederick Krass can be reached on 571-272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

evidences it was well known in the cancer treatment art to administer agents intratumorally in order to minimize systemic drug levels and the corresponding cell effects.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Benjamin Packard/
Examiner, Art Unit 1612

/Gollamudi S Kishore/
Primary Examiner, Art Unit 1612